Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Br J Haematol. 2013 Jul;162(1):87-92. doi: 10.1111/bjh.12356. Epub 2013 Apr 25.
We evaluated the prognostic significance of CD43 (SPN), a membrane glycoprotein, in 140 patients with diffuse large B-cell lymphoma (DLBCL) by tissue microarray (TMA) immunostaining, and gene expression profiling (GEP) in 43 patients. CD43 protein was expressed in 19% of the cases and was strongly related to the non-germinal centre B-cell (non-GCB) subgroup by both TMA and GEP. Patients with CD43(+) DLBCL had an inferior 3-year overall survival (OS) compared to those with CD43(-) DLBCL (50% vs. 76%, P = 0·01). Within the non-GCB subgroup, patients with CD43(+) DLBCL had a particularly poor 3-year OS (32% vs. 71%, P < 0·001). Gene set enrichment analysis within the activated B-cell subgroup revealed significant enrichment in the stromal-1 signature in CD43(-) cases. We conclude that CD43 is an adverse prognostic marker in DLBCL, and is preferentially expressed in the non-GCB subgroup. The dismal outcome of CD43(+) cases in the non-GCB subgroup may be explained, at least in part, by a less favourable microenvironment.
我们通过组织微阵列（TMA）免疫染色评估了 140 例弥漫性大 B 细胞淋巴瘤（DLBCL）患者中膜糖蛋白 CD43（SPN）的预后意义，并对 43 例患者进行了基因表达谱（GEP）分析。CD43 蛋白在 19%的病例中表达，并通过 TMA 和 GEP 均与非生发中心 B 细胞（non-GCB）亚组强烈相关。与 CD43(-)DLBCL 患者相比，CD43(+)DLBCL 患者的 3 年总生存率（OS）较低（50% vs. 76%，P=0.01）。在 non-GCB 亚组中，CD43(+)DLBCL 患者的 3 年 OS 尤其差（32% vs. 71%，P<0.001）。在激活 B 细胞亚组内进行的基因集富集分析显示，CD43(-)病例中基质-1 特征明显富集。我们得出结论，CD43 是 DLBCL 的不良预后标志物，并且在 non-GCB 亚组中优先表达。CD43(+)病例在 non-GCB 亚组中的不良预后至少部分可以通过不太有利的微环境来解释。
